Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.